Association between Circulating Growth Differentiation Factor 15 and Cirrhotic Primary Biliary Cholangitis

Table 1

Clinical and laboratory parameters of PBC patients and healthy controls.

Feature	Healthy controls ()	Non-cirrhotic PBC patients ()	Cirrhotic PBC patients ()
Age (years)
Gender (male)	4	3	7
Weight change (kg)			^#
Weight change (%)			^#
>5% within past 6 months	0	2	4
BMI (kg/m^2)			^#
Low BMI (<18.5 if <70 years)	0	2	6
CRP (mg/L)
	0	13	12
Malnutrition (, %)	0	4 (15.38%)	9 (45%)^#
GDF15 (pg/mL)			^#
ALT (U/L)
AST (U/L)
TBIL (μmol/L)
DBIL (μmol/L)
GGT (U/L)
ALP (U/L)
TBA (μmol/L)			^#
ALB (g/L)			^#
GLB (g/L)
INR			^#
MELD score	N/A		^#
Mayo risk score	N/A		^#
ANA positive	0	25	19
Anti-SP100	0	1	1
Anti-GP210	0	1	4
AMA positive	0	22	16
AMA-M2 positive	0	9	6

compared to corresponding values in healthy controls. ^# compared to corresponding values in non-cirrhotic PBC patients. PBC: primary biliary cholangitis; BMI: body mass index; GDF15: growth differentiation factor 15; AST: aspartate aminotransferase; ALT: alanine aminotransferase; TBIL: total bilirubin; DBIL: direct bilirubin; GGT: gamma-glutamyl transpeptidase; ALP: alkaline phosphatase; TBA: total bile acids; ALB: albumin; GLB: globulin; INR: international normalized ratio; CRP: C-reactive protein; MELD score: Model for End-stage Liver Disease score.